- Home
- MKL vs TEVA Comparison
MKL vs TEVA Comparison
Compare MKL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKL | TEVA |
|---|---|---|
| Founded | 1930 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4B | 30.2B |
| IPO Year | 1986 | N/A |
Fundamental Metrics
Financial Performance| Metric | MKL | TEVA |
|---|---|---|
| Price | $2,051.09 | $28.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $2,025.00 | $27.00 |
| AVG Volume (30 Days) | 42.6K | ★ 11.4M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 142.27 | 0.62 |
| Revenue | $16,210,307,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | N/A | $4.74 |
| Revenue Next Year | N/A | $0.48 |
| P/E Ratio | ★ $14.39 | $46.12 |
| Revenue Growth | N/A | ★ 0.02 |
| 52 Week Low | $1,621.89 | $12.47 |
| 52 Week High | $2,109.91 | $28.68 |
Technical Indicators
Market Signals| Indicator | MKL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 80.93 |
| Support Level | $2,018.46 | $24.01 |
| Resistance Level | $2,063.13 | $26.96 |
| Average True Range (ATR) | 32.67 | 0.68 |
| MACD | -6.09 | 0.19 |
| Stochastic Oscillator | 41.47 | 94.65 |
Price Performance
Historical ComparisonAbout MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.